يعرض 1 - 9 نتائج من 9 نتيجة بحث عن '"FENÓMENOS Y PROCESOS::fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásica"', وقت الاستعلام: 0.81s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Chumsri S Jacoby Center for Breast Health, Mayo Clinic, Jacksonville, FL, USA. Li Z, Serie DJ Department of Health and Human Services, Mayo Clinic, Jacksonville, FL, USA. Norton N Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA. Mashadi-Hossein A NanoString, Inc., Seattle, WA, USA. Tenner K Department of Health and Human Services, Mayo Clinic, Rochester, MN, USA. Saura C Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: NPJ Breast Cancer;8; https://doi.org/10.1038/s41523-022-00430-0Test; Chumsri S, Li Z, Serie DJ, Norton N, Mashadi-Hossein A, Tenner K, et al. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. NPJ Breast Cancer. 2022 May 24;8:68.; https://hdl.handle.net/11351/8055Test; 000799816800001

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Vargas-Accarino E, Herrera-Montávez C Grup de Recerca en Patologia Molecular Translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ramón Y Cajal S Patologia Molecular Translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER de Cáncer (CIBERONC), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 3-5, 28029 Madrid, Spain. Aasen T Patologia Molecular Translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER de Cáncer (CIBERONC), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 3-5, 28029 Madrid, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf; application/mp4

    العلاقة: International Journal of Molecular Sciences;22(9); https://doi.org/10.3390/ijms22094929Test; info:eu-repo/grantAgreement/ES/PE2013-2016/CPII16%2F00042; Vargas-Accarino E, Herrera-Montávez C, Ramón y Cajal S, Aasen T. Spontaneous Cell Detachment and Reattachment in Cancer Cell Lines: An In Vitro Model of Metastasis and Malignancy. Int J Mol Sci. 2021 May;22(9):4929.; https://hdl.handle.net/11351/6874Test; 000650381000001

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, García-Montolio M, Ballaré C, Blanco E, Gutiérrez A, Aranda S Epigenetics Events in Cancer Laboratory, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Barcelona, Spain. Gómez A Grup de Recerca en Reumatologia, Servei de Reumatologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Frontiers in Cell and Developmental Biology;9; https://doi.org/10.3389/fcell.2021.655201Test; info:eu-repo/grantAgreement/ES/PE2013-2016/BFU2016-75008-P; info:eu-repo/grantAgreement/ES/PE2017-2020/PID2019-108322GB-100; info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01814; García-Montolio M, Ballaré C, Blanco E, Gutiérrez A, Aranda S, Gómez A, et al. Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells. Front Cell Dev Biol. 2021 Apr 29;9:665201.; https://hdl.handle.net/11351/6701Test; 000649663800001

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Granado-Martínez P, Garcia-Ortega S, González-Sánchez E, McGrail K, Selgas R, Gil R, Recio JA Grup de Recerca Biomèdica en Melanoma. Models Animals de Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grueso J Grup de Recerca Biomèdica en Melanoma. Models Animals de Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Naldaiz-Gastesi N Grup de Recerca Biomèdica en Melanoma. Models Animals de Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Biodonostia, Neurosciences Area, Group of Neuromuscular Diseases, San Sebastian 20014, Spain. Rhodes AC Grup de Recerca Biomèdica en Melanoma. Models Animals de Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic of Barcelona, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036, Spain. Hernandez-Losa J Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Ferrer B Grup de Recerca Biomèdica en Melanoma. Models Animals de Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Canals F Proteomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Villanueva J, Méndez O Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Muñoz-Couselo E Grup de Recerca Biomèdica en Melanoma. Models Animals de Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Clinical Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Communications Biology;3; https://doi.org/10.1038/s42003-020-1092-0Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI14%2F00375; info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00043; info:eu-repo/grantAgreement/ES/PE2013-2016/AC16%2F00019; Granado-Martínez P, Garcia-Ortega S, González-Sánchez E, McGrail K, Selgas R, Grueso J, et al. STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation. Commun Biol. 2020 Jul 9;3:366.; https://hdl.handle.net/11351/6261Test; 000552080500009

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Wang S, Somisetty VS, Bai B Cell Cycle Regulations Group, Nordic EMBL Partnership, Centre for Molecular Medicine Norway (NCMM), University of Oslo, Blindern, P.O. 1137, 0318 Oslo, Norway. Chernukhin I Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK. Niskanen H, Kaikkonen MU A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland. Bellet M Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Oncogene;39(40); https://doi.org/10.1038/s41388-020-01435-4Test; Wang S, Somisetty VS, Bai B, Chernukhin I, Niskanen H, Kaikkonen MU, et al. The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen. Oncogene. 2020 Oct 1;39(40):6300–12.; https://hdl.handle.net/11351/6516Test; 000562669100001

  6. 6
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Medina A, Jiménez C, Sarasquete ME, González M, Chillón MC, Balanzategui A Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain. Gironella M Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Blood Cancer Journal;10; https://doi.org/10.1038/s41408-020-0283-8Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F01956; info:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F12%2F00233; info:eu-repo/grantAgreement/ES/PE2013-2016/CPII18%2F00028; Medina A, Jiménez C, Sarasquete ME, González M, Chillón MC, Balanzategui A, et al. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. Blood Cancer J. 2020 Feb 6;10:14.; https://hdl.handle.net/11351/6280Test; 000512747500001

  7. 7
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Di Cosimo S, Appierto V, Silvestri M Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Pizzamiglio S Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Baselga J, Nuciforo P Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Piccart M Department of Medical Oncology, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B), Brussels, Belgium, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf; image/tiff

    العلاقة: International Journal of Molecular Sciences;21(4); https://www.mdpi.com/1422-0067/21/4/1386Test; Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, et al. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. Int J Mol Sci. 2020 Feb 18;21(4):1386.; https://hdl.handle.net/11351/6250Test; 000522524400213

  8. 8
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Cebrià-Costa JP, Pascual-Reguant L, Serra-Bardenys G, Querol J, Cosín M, Nuciforo P, Rodilla V, Peiró S Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Gonzalez-Perez A Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, 08028 Barcelona, Spain. Verde G Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain. Bernado-Morales C Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red en Oncología (CIBERONC), 08035 Barcelona, Spain. Arribas J Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red en Oncología (CIBERONC), 08035 Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf; image/jpeg

    العلاقة: Oncogene;39(1); https://doi.org/10.1038/s41388-019-0969-1Test; info:eu-repo/grantAgreement/ES/1PN/2008-2011/PI12%2F01250; info:eu-repo/grantAgreement/ES/2PN/CP08%2F00223; info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00253; info:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F12%2F00449; info:eu-repo/grantAgreement/ES/PE2013-2016/SAF2013-48849-C2-1-R; info:eu-repo/grantAgreement/ES/PE2013-2016/IJCI-2014-20723; Cebrià-Costa JP, Pascual-Reguant L, Gonzalez-Perez A, Serra-Bardenys G, Querol J, Cosín M, et al. LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells. Oncogene. 2020 Jan 2;39(1):79–121.; https://hdl.handle.net/11351/6508Test; 000509849200007

  9. 9
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Pascual T, Paré L Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. Martin M Medical Oncology Department, Hospital Gregorio Marañón, Universidad Complutense, Madrid, Spain. GEICAM (Spanish Breast Cancer Group), Madrid, Spain. Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain. Fernández-Martínez A Department of Genetics, University of North Carolina, Chapel Hill, NC, United States. Alba E GEICAM (Spanish Breast Cancer Group), Madrid, Spain. Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain. Medical Oncology Department, Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain. Rodríguez-Lescure Á GEICAM (Spanish Breast Cancer Group), Madrid, Spain. Medical Oncology Department, Hospital Universitario de Elche, Elche, Spain. Cortés J IOB Institute of Oncology, Quironsalud Group, Madrid, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Frontiers in Oncology;9(303); https://www.frontiersin.org/articles/10.3389/fonc.2019.00303/fullTest; info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00904; Pascual T, Martin M, Fernández-Martínez A, Paré L, Alba E, Rodríguez-Lescure Á, et al. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Front Oncol. 2019 Apr 26;9(303).; https://hdl.handle.net/11351/5779Test; 000466075200001